Healthcare
Live Price
Offline$26.09
-0.08% today
1Y Change
+16.35%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TruBridge, Inc. (TBRG) is a Healthcare stock with a market cap of $390.00M and listed on NASDAQ. The stock last traded around $26.09 and up 16.3% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +1.2%, EPS growth of +121.0%, a dividend yield of 0.0%. What stands out right now is revenue +1.2%, EPS +121.0%, free cash flow +173.5% with operating margin 6.0% and ROIC 6.0%. Valuation already assumes a fairly strong business story at P/E 85.8 and price/sales 1.1. Stock Foundry combines TBRG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TBRG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TBRG Max Drawdown
-40.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TBRG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$280.6M
-14.1% YoY
FY Net Income
$18.4M
+16.2% YoY
Free Cash Flow
$37.5M
+188.0% YoY
Revenue Growth
+1.2%
EPS Growth
+121.0%
Gross Margin
53.0%
Net Margin
1.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 347M | 343M | 339M | 327M | 281M |
| Gross Profit | 184M | 174M | 164M | 160M | 145M |
| Operating Income | 21M | 7M | -43M | 23M | 25M |
| EBITDA | 42M | 35M | -15M | 48M | 43M |
| Net Income | 4M | -20M | -46M | 16M | 18M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25M | 12M | 4M | 7M | 11M |
| Total Assets | 403M | 394M | 432M | 431M | 383M |
| Total Liabilities | 225M | 226M | 248M | 199M | 161M |
| Shareholder Equity | 178M | 169M | 184M | 232M | 223M |
| Total Debt | 167M | 175M | 203M | 147M | 106M |
| Net Debt | 142M | 162M | 199M | 140M | 95M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
48M
+47.5% YoY
Capital Expenditures
10M
+46.9% YoY
Free Cash Flow
37M
+188.0% YoY
Key ratios
Gross Margin
53.0%
Operating Margin
6.0%
Net Margin
1.3%
ROE
2.5%
Debt / Equity
0.94x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.